In VivoThe idea of manipulating biology to produce therapeutics is not new. In 1978, Eli Lilly and Company and Genentech, Inc. developed the first recombinant DNA human insulin by inserting the human gen
ScripArbor Biotechnologies , Acrivon Therapeutics Inc. and bit.bio are the newest members of the biopharma venture capital mega-round club after the companies announced series B rounds totaling $215m, $100
In VivoStart-Ups Across Health Care There are approximately 140,000 fatalities a year from postpartum hemorrhage, mostly in low- to middle-income countries, and thus a pressing need to reduce mortality. A ne
ScripMolecular Assemblies Inc. 3210 Merryfield Row San Diego, CA 92121 Phone: (619) 316-4662 Web Site: www.molecularassemblies.com Contact: Curt Becker, CEO Industry Segment: Genomics Tools Busi